Clinical Trial Update: Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating alemtuzumab in relapsed or refractory advanced mycosis fungoides or Sézary syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycosis Fungoides
• Sézary Syndrome

Drugs mentioned

• Alemtuzumab (Campath) (alemtuzumab)

Snippet

Sponsor: Northwestern University | Conditions: Lymphoma | Phase 2 | Status: COMPLETED